References
Amit, D., & Hochberg, A. (2010). Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med, 8 , 134. doi: 10.1186/1479-5876-8-134
Astrada, S., Fernandez Masso, J. R., Vallespi, M. G., & Bollati-Fogolin, M. (2018). Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity.Molecules, 23 (4). doi: 10.3390/molecules23040801
Astrada, S., Gomez, Y., Barrera, E., Obal, G., Pritsch, O., Pantano, S., . . . Bollati-Fogolin, M. (2016). Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552. J Pept Sci, 22 (11-12), 711-722. doi: 10.1002/psc.2934
Bartuzi, P., Billadeau, D. D., Favier, R., Rong, S., Dekker, D., Fedoseienko, A., . . . van de Sluis, B. (2016). CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nat Commun, 7 , 10961. doi: 10.1038/ncomms10961
Borghouts, C., Kunz, C., & Groner, B. (2005). Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci, 11 (11), 713-726. doi: 10.1002/psc.717
Bucci, C., Parton, R. G., Mather, I. H., Stunnenberg, H., Simons, K., Hoflack, B., & Zerial, M. (1992). The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell, 70 (5), 715-728. doi: 10.1016/0092-8674(92)90306-w
Burstein, E., Hoberg, J. E., Wilkinson, A. S., Rumble, J. M., Csomos, R. A., Komarck, C. M., . . . Duckett, C. S. (2005). COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem, 280 (23), 22222-22232. doi: 10.1074/jbc.M501928200
Drevillon, L., Tanguy, G., Hinzpeter, A., Arous, N., de Becdelievre, A., Aissat, A., . . . Fanen, P. (2011). COMMD1-mediated ubiquitination regulates CFTR trafficking. PLoS One, 6 (3), e18334. doi: 10.1371/journal.pone.0018334
Drew, D. A., Cao, Y., & Chan, A. T. (2016). Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer, 16 (3), 173-186. doi: 10.1038/nrc.2016.4
Fedoseienko, A., Wieringa, H. W., Wisman, G. B., Duiker, E., Reyners, A. K., Hofker, M. H., . . . van Vugt, M. A. (2016). Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS One, 11 (10), e0165385. doi: 10.1371/journal.pone.0165385
Fernandez Masso, J. R., Oliva Arguelles, B., Tejeda, Y., Astrada, S., Garay, H., Reyes, O., . . . Vallespi, M. G. (2013). The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells. J Amino Acids, 2013 , 251398. doi: 10.1155/2013/251398
Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today, 20 (1), 122-128. doi: 10.1016/j.drudis.2014.10.003
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144 (5), 646-674. doi: 10.1016/j.cell.2011.02.013
Hawai, S. M., Al-Zayer, M., Ali, M. M., Niu, Y., Alawad, A., Aljofan, M., . . . Altuwaijri, S. (2013). Dogs: active role model for cancer studies—a review.
Heitz, F., Morris, M. C., & Divita, G. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol, 157 (2), 195-206. doi: 10.1111/j.1476-5381.2009.00057.x
Hoskin, D. W., & Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial peptides.Biochim Biophys Acta, 1778 (2), 357-375. doi: 10.1016/j.bbamem.2007.11.008
Huang, W., Seo, J., Willingham, S. B., Czyzewski, A. M., Gonzalgo, M. L., Weissman, I. L., & Barron, A. E. (2014). Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. PLoS One, 9 (2), e90397. doi: 10.1371/journal.pone.0090397
Luo, J., Solimini, N. L., & Elledge, S. J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell, 136 (5), 823-837. doi: 10.1016/j.cell.2009.02.024
Maine, G. N., Mao, X., Komarck, C. M., & Burstein, E. (2007). COMMD1 promotes the ubiquitination of NF-kappaB subunits through a cullin-containing ubiquitin ligase.EMBO J, 26 (2), 436-447. doi: 10.1038/sj.emboj.7601489
Nunez de Villavicencio-Diaz, T., Ramos Gomez, Y., Oliva Arguelles, B., Fernandez Masso, J. R., Rodriguez-Ulloa, A., Cruz Garcia, Y., . . . Guerra Vallespi, M. (2015). Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells. J Proteomics, 126 , 163-171. doi: 10.1016/j.jprot.2015.05.024
O’Hara, A., Simpson, J., Morin, P., Loveridge, C. J., Williams, A. C., Novo, S. M., & Stark, L. A. (2014). p300-mediated acetylation of COMMD1 regulates its stability, and the ubiquitylation and nucleolar translocation of the RelA NF-kappaB subunit. J Cell Sci, 127 (Pt 17), 3659-3665. doi: 10.1242/jcs.149328
Patrignani, P., & Patrono, C. (2016). Aspirin and Cancer. J Am Coll Cardiol, 68 (9), 967-976. doi: 10.1016/j.jacc.2016.05.083
Phillips-Krawczak, C. A., Singla, A., Starokadomskyy, P., Deng, Z., Osborne, D. G., Li, H., . . . Burstein, E. (2015). COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Mol Biol Cell, 26 (1), 91-103. doi: 10.1091/mbc.E14-06-1073
Riera-Romo, M. (2018). COMMD1: A Multifunctional Regulatory Protein. J Cell Biochem, 119 (1), 34-51. doi: 10.1002/jcb.26151
Rodriguez-Corona, U., Sobol, M., Rodriguez-Zapata, L. C., Hozak, P., & Castano, E. (2015). Fibrillarin from Archaea to human. Biol Cell, 107 (6), 159-174. doi: 10.1111/boc.201400077
Rodriguez-Ulloa, A., Gil, J., Ramos, Y., Hernandez-Alvarez, L., Flores, L., Oliva, B., . . . Guerra-Vallespi, M. (2015). Proteomic Study to Survey the CIGB-552 Antitumor Effect.Biomed Res Int, 2015 , 124082. doi: 10.1155/2015/124082
Rowell, J. L., McCarthy, D. O., & Alvarez, C. E. (2011). Dog models of naturally occurring cancer.Trends Mol Med, 17 (7), 380-388. doi: 10.1016/j.molmed.2011.02.004
Ter-Avetisyan, G., Tunnemann, G., Nowak, D., Nitschke, M., Herrmann, A., Drab, M., & Cardoso, M. C. (2009). Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem, 284 (6), 3370-3378. doi: 10.1074/jbc.M805550200
Thoms, H. C., Loveridge, C. J., Simpson, J., Clipson, A., Reinhardt, K., Dunlop, M. G., & Stark, L. A. (2010). Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent ubiquitination. Cancer Res, 70 (1), 139-149. doi: 10.1158/0008-5472.CAN-09-1397
Tunnemann, G., Ter-Avetisyan, G., Martin, R. M., Stockl, M., Herrmann, A., & Cardoso, M. C. (2008). Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J Pept Sci, 14 (4), 469-476. doi: 10.1002/psc.968
Vallespi, M. G., Alvarez-Obregon, J. C., Rodriguez-Alonso, I., Montero, T., Garay, H., Reyes, O., & Arana, M. J. (2003). A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. Int Immunopharmacol, 3 (2), 247-256. doi: 10.1016/S1567-5769(02)00277-1
Vallespi, M. G., Colas, M., Garay, H., Reyes, O., & Arana, M. J. (2004). Differential regulation of Th1/Th2 in relevant tissues for sepsis pathogenesis with a Limulus anti-LPS factor-derived peptide increases survival in Gram-positive sepsis. Int Immunopharmacol, 4 (10-11), 1343-1351. doi: 10.1016/j.intimp.2004.05.019
Vallespi, M. G., Fernandez, J. R., Torrens, I., Garcia, I., Garay, H., Mendoza, O., . . . Reyes, O. (2010). Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region. J Pept Sci, 16 (1), 40-47. doi: 10.1002/psc.1192
Vallespi, M. G., Pimentel, G., Cabrales-Rico, A., Garza, J., Oliva, B., Mendoza, O., . . . Reyes, O. (2014). Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models. J Pept Sci, 20 (11), 850-859. doi: 10.1002/psc.2676
Vallespi, M. G., Rodriguez, J. C., Seoane, L. C., Alvarez, P., Santana, H., Garay, H., . . . Reyes, O. (2017). The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552. Res Vet Sci, 114 , 502-510. doi: 10.1016/j.rvsc.2017.09.029
van de Sluis, B., Groot, A. J., Vermeulen, J., van der Wall, E., van Diest, P. J., Wijmenga, C., . . . Vooijs, M. (2009). COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70. PLoS One, 4 (10), e7332. doi: 10.1371/journal.pone.0007332
van de Sluis, B., Mao, X., Zhai, Y., Groot, A. J., Vermeulen, J. F., van der Wall, E., . . . Burstein, E. (2010). COMMD1 disrupts HIF-1α/β dimerization and inhibits human tumor cell invasion. J Clin Invest., 120 (6), 2119-2130. doi: doi:10.1172/JCI40583
Vonk, W. I., Wijmenga, C., Berger, R., van de Sluis, B., & Klomp, L. W. (2010). Cu,Zn superoxide dismutase maturation and activity are regulated by COMMD1. J Biol Chem, 285 (37), 28991-29000. doi: 10.1074/jbc.M110.101477
Werle, M., Bernkop-Schnurcch. (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino acids, 30 (4), 351-367.
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014). Peptide-based cancer therapy: opportunity and challenge. Cancer Lett, 351 (1), 13-22. doi: 10.1016/j.canlet.2014.05.002
Yavari, B., Mahjub, R., Saidijam, M., Raigani, M., & Soleimani, M. (2018). The Potential Use of Peptides in Cancer Treatment. Curr Protein Pept Sci, 19 (8), 759-770. doi: 10.2174/1389203719666180111150008
Yeh, D. W., Chen, Y. S., Lai, C. Y., Liu, Y. L., Lu, C. H., Lo, J. F., . . . Chuang, T. H. (2016). Downregulation of COMMD1 by miR-205 promotes a positive feedback loop for amplifying inflammatory- and stemness-associated properties of cancer cells. Cell Death Differ, 23 (5), 841-852. doi: 10.1038/cdd.2015.147.